07:00 , May 25, 2015 |  BC Week In Review  |  Company News

Roche, Astellas deal

Roche’s Ventana Medical Systems Inc. unit will develop companion diagnostics for compounds being developed by Astellas, including the pharma’s ASP5878. The fibroblast growth factor (FGF) receptor (FGFR) inhibitor is in Phase I...
08:00 , Dec 8, 2014 |  BC Week In Review  |  Company News

Qiagen, Astellas deal

The companies to develop and commercialize companion diagnostics for Astellas’ pipeline. Qiagen develops assays based on PCR, next-generation sequencing and multi-modal testing technologies using liquid and tissue biopsies. The deal will initially focus on Astellas’...